New Parkinson's drug HER-096 passes first safety check in small trial

NCT ID NCT06659562

Completed Disease control Sponsor: Herantis Pharma Plc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested the safety of a new drug called HER-096 for Parkinson's disease. It involved 32 people: healthy volunteers who got a single dose, and Parkinson's patients who received multiple doses over four weeks. The main goal was to check for side effects and how the body handles the drug, not yet to see if it improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HER-096
What this could lead to: If successful, this could pave the way for larger studies testing whether HER-096 can slow or modify Parkinson's disease progression.
What could go wrong: This is a very early Phase 1 safety trial with only 32 people. It is not designed to prove whether the drug works for Parkinson's, and many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE, IDIOPATHIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system disorder neurodegenerative disease Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE, IDIOPATHIC

Contacts and locations

Locations

Clinical Research Services Turku - CRST Oy

Turku, Finland, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.